Nature Communications (Jul 2021)
Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease
- Tatsuma Ban,
- Masako Kikuchi,
- Go R. Sato,
- Akio Manabe,
- Noriko Tagata,
- Kayo Harita,
- Akira Nishiyama,
- Kenichi Nishimura,
- Ryusuke Yoshimi,
- Yohei Kirino,
- Hideyuki Yanai,
- Yoshiko Matsumoto,
- Shuichi Suzuki,
- Hiroe Hihara,
- Masashi Ito,
- Kappei Tsukahara,
- Kentaro Yoshimatsu,
- Tadashi Yamamoto,
- Tadatsugu Taniguchi,
- Hideaki Nakajima,
- Shuichi Ito,
- Tomohiko Tamura
Affiliations
- Tatsuma Ban
- Department of Immunology, Yokohama City University Graduate School of Medicine
- Masako Kikuchi
- Department of Immunology, Yokohama City University Graduate School of Medicine
- Go R. Sato
- Department of Immunology, Yokohama City University Graduate School of Medicine
- Akio Manabe
- Department of Immunology, Yokohama City University Graduate School of Medicine
- Noriko Tagata
- Department of Immunology, Yokohama City University Graduate School of Medicine
- Kayo Harita
- Department of Immunology, Yokohama City University Graduate School of Medicine
- Akira Nishiyama
- Department of Immunology, Yokohama City University Graduate School of Medicine
- Kenichi Nishimura
- Department of Pediatrics, Yokohama City University Graduate School of Medicine
- Ryusuke Yoshimi
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine
- Yohei Kirino
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine
- Hideyuki Yanai
- Department of Inflammology, Social Cooperation Program, Research Center for Advanced Science and Technology, University of Tokyo
- Yoshiko Matsumoto
- Tsukuba Research Laboratories, Eisai Co., Ltd.
- Shuichi Suzuki
- Tsukuba Research Laboratories, Eisai Co., Ltd.
- Hiroe Hihara
- Tsukuba Research Laboratories, Eisai Co., Ltd.
- Masashi Ito
- Tsukuba Research Laboratories, Eisai Co., Ltd.
- Kappei Tsukahara
- Tsukuba Research Laboratories, Eisai Co., Ltd.
- Kentaro Yoshimatsu
- Tsukuba Research Laboratories, Eisai Co., Ltd.
- Tadashi Yamamoto
- Cell Signal Unit, Okinawa Institute of Science and Technology Graduate University
- Tadatsugu Taniguchi
- Department of Inflammology, Social Cooperation Program, Research Center for Advanced Science and Technology, University of Tokyo
- Hideaki Nakajima
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine
- Shuichi Ito
- Department of Pediatrics, Yokohama City University Graduate School of Medicine
- Tomohiko Tamura
- Department of Immunology, Yokohama City University Graduate School of Medicine
- DOI
- https://doi.org/10.1038/s41467-021-24609-4
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
IRF5 is a potential target for therapy in systemic lupus erythematosus (SLE). Here the authors show using mouse SLE-like models that genetic or chemical inhibition of IRF5 after SLE onset could be more effective than, or an add on for, currently utilised type I interferon inhibition.
